Increasing Adoption of Prostacyclin and Prostacyclin Analogs to Bode Well with Global Pulmonary Arterial Hypertension (PAH) Market
Transparency Market Research (TMR), a market research company, throws light on the top factors fuelling and restraining the growth of the pulmonary arterial hypertension (PAH) market. The strategies adopted by key players for a better penetration into the market have also been elaborated upon in this study.
Q. What factors will positively and negatively impact the development of the global pulmonary arterial hypertension (PAH) market?
The global pulmonary arterial hypertension (PAH) market is predicted to experience immense growth in the coming years owing to the growing occurrence of blood pressure disorders of artery, vein, or capillaries. In addition, the growing popularity of pulmonary arterial hypertension treatments, the enhanced drug delivery, and the growing aging population will provide impetus to the development of the market. The growing disposable income along with the rising investments in the sector of healthcare will augment the growth of this market.
Furthermore, the growing occurrence of diastolic malfunction of left ventricle or heart failures has also positively impacted the development of this market. The introduction of breakthrough therapy for treating PAH will provide ample growth opportunities for the manufacturers of drugs. On the other hand, the growth of the pulmonary arterial hypertension (PAH) market will be impeded by the patent expiry of key PAH drugs including Letairis, Tracleer, Tyvaso, and Adcirca. The patent expiry of these drugs is poised to directly impact the revenue of the market in the coming years.
Q. Which drug class is poised to hold lucrative opportunities in the market in the coming years and why?
In terms of drug class, the PAH market is categorized into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, Soluble Guanylate Cyclase (sGC) stimulators, and phosphodiesterase-5 (PDE-5) inhibitors. Amongst these, the segment of ERAs held a significant share of 55.8% on the basis of revenue in 2013. However, the drug class of prostacyclin and prostacyclin analogs is predicted to hold lucrative opportunities in the market in the coming years, primarily owing to Orenitram’s (treprostinil extended release tablet) approval in December 2013.
Q. What ways are the prominent players adopting in order to maximize their revenues in the market?
The leading players in the PAH market are Gilead Sciences, Inc., Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., Novartis International AG, United Therapeutics Corporation, Pfizer, Inc., and GlaxoSmithKline Plc. These companies are highly implementing strategic collaborations, mergers and acquisitions, and geographical expansions for maximizing their revenues in this market.